Autobahn Therapeutics Raises $100 Million in Funding to Advance Clinical Trials and Expand Operations

Autobahn Therapeutics raises $100M in Series C Funding

Autobahn Therapeutics (Linkedin), a biotechnology research company based in the United States, has secured $100 million in Series C funding. With a focus on neuropsychiatric and neuroimmunologic disorders, Autobahn Therapeutics is poised to advance their lead program, ABX-002, and conduct Phase 2 clinical trials.

Funding Amount: $100 million

Industry: Biotechnology Research

Employee Count: 11-50

CEO: Kevin Finney (CEO Linkedin)

What Autobahn Therapeutics needs to buy: Autobahn Therapeutics is seeking collaborations with clinical research organizations, manufacturers, and regulatory experts. Companies specializing in clinical research and development, manufacturing and supply chain solutions, and regulatory compliance can support Autobahn Therapeutics in advancing their clinical candidates and navigating the complex biotechnology and pharmaceutical industry landscape.